Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: GlobalData | PRODUCT CODE: 1766816

Cover Image

PUBLISHER: GlobalData | PRODUCT CODE: 1766816

Japan Oncology Market Outlook to 2033 - Colorectal Cancer Screening Tests, EGFR Tests, KRAS Tests and Others

PUBLISHED:
PAGES: 150 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
PDF (Single User License)
USD 4995
PDF (Site License)
USD 9990
PDF (Global License)
USD 14985

Add to Cart

GlobalData's "Japan Oncology Market Outlook to 2033" is a comprehensive databook report, covering key market data on the Japan Oncology market. The databook report provides value (USD), volume (units) and average prices (USD) within market segments - Colorectal Cancer Screening Tests, EGFR Tests, KRAS Tests, HER2 Tests, BRCA Tests, ALK Tests, BRAF Tests, BCR-ABL Tests and PD-L1 Tests

The Japan Oncology Market report provides key information and data on -

  • Annualized market revenues (USD), volume (units) and average prices (USD) data for each of the market segments. Data is provided from 2018 to 2033.
  • 2024 company share data for Oncology Market.
  • Global corporate-level profiles of key companies operating within the Japan Oncology Market. Based on the availability of data for the particular category and country, information related to pipeline products, news and deals is also available in the report.

Scope

Japan Oncology is segmented as follows -

  • Colorectal Cancer Screening Tests
  • EGFR Tests
  • KRAS Tests
  • HER2 Tests
  • BRCA Tests
  • ALK Tests
  • BRAF Tests
  • BCR-ABL Tests
  • PD-L1 Tests

Reasons to Buy

The Japan Oncology Market report helps you to develop -

  • Business strategies by identifying the key market segments poised for strong growth in the future.
  • Market-entry and market expansion strategies.
  • Design competition strategies by identifying who-stands-where in the market.
  • Develop investment strategies by identifying the key market segments expected to register strong growth in the near future.
  • Understand the key distribution channels and what's the most preferred mode of product distribution - Identify, understand and capitalize.
Product Code: GDME25619CCDB

Table of Contents

1 Table of Contents

  • 1.1 List of Tables
  • 1.2 List of Figures

2 Introduction

  • 2.1 What Is This Report About?
  • 2.2 Oncology Market Segmentation
  • 2.3 Definitions of Markets Covered in the Report

3 Oncology Market, Japan

  • 3.1 Oncology Market, Japan, Revenue ($m), 2018-2033
    • 3.1.1 ALK Tests Market, Japan, Revenue ($m), by Segment, 2018-2033
    • 3.1.2 BCR-ABL Tests Market, Japan, Revenue ($m), by Segment, 2018-2033
    • 3.1.3 BRAF Tests Market, Japan, Revenue ($m), by Segment, 2018-2033
    • 3.1.4 BRCA Tests Market, Japan, Revenue ($m), by Segment, 2018-2033
    • 3.1.5 Colorectal Cancer Screening Tests Market, Japan, Revenue ($m), by Segment, 2018-2033
    • 3.1.6 EGFR Tests Market, Japan, Revenue ($m), by Segment, 2018-2033
    • 3.1.7 HER2 Tests Market, Japan, Revenue ($m), by Segment, 2018-2033
    • 3.1.8 KRAS Tests Market, Japan, Revenue ($m), by Segment, 2018-2033
  • 3.2 Oncology Market, Japan, Volume (Units), 2018-2033
    • 3.2.1 ALK Tests Market, Japan, Volume (Units), by Segment, 2018-2033
    • 3.2.2 BCR-ABL Tests Market, Japan, Volume (Units), by Segment, 2018-2033
    • 3.2.3 BRAF Tests Market, Japan, Volume (Units), by Segment, 2018-2033
    • 3.2.4 BRCA Tests Market, Japan, Volume (Units), by Segment, 2018-2033
    • 3.2.5 Colorectal Cancer Screening Tests Market, Japan, Volume (Units), by Segment, 2018-2033
    • 3.2.6 EGFR Tests Market, Japan, Volume (Units), by Segment, 2018-2033
    • 3.2.7 HER2 Tests Market, Japan, Volume (Units), by Segment, 2018-2033
    • 3.2.8 KRAS Tests Market, Japan, Volume (Units), by Segment, 2018-2033
  • 3.3 Oncology Market, Japan, Average Price ($) , 2018-2033
  • 3.4 Oncology Market, Japan, Company Share by Revenue ($m), 2024

4 Overview of Key Companies in Japan, Oncology Market

  • 4.1 F. Hoffmann-La Roche Ltd
    • 4.1.1 Company Overview
  • 4.2 Agilent Technologies Inc
    • 4.2.1 Company Overview
  • 4.3 Abbott Laboratories
    • 4.3.1 Company Overview
  • 4.4 BioGenex Laboratories Inc
    • 4.4.1 Company Overview
  • 4.5 Danaher Corp
    • 4.5.1 Company Overview
  • 4.6 Amoy Diagnostics Co Ltd
    • 4.6.1 Company Overview
  • 4.7 Alfresa Pharma Corp
    • 4.7.1 Company Overview
  • 4.8 Qiagen NV
    • 4.8.1 Company Overview
  • 4.9 Eiken Chemical Co Ltd
    • 4.9.1 Company Overview
  • 4.10 SENTINEL CH SpA
    • 4.10.1 Company Overview

5 Oncology Market Pipeline Products

6 Financial Deals Landscape

  • 6.1 Debt Offerings
    • 6.1.1 Astellas Pharma Prices USD545.6 Million in Public Offering of 0.87% Series 5 Unsecured Bonds Due 2029
    • 6.1.2 Astellas Pharma Prices USD136.4 Million in Public Offering of 1.038% Series 6 Unsecured Bonds Due 2031
  • 6.2 Venture Financing
    • 6.2.1 The IT Lab Secures Venture Financing

7 Recent Developments

  • 7.1 Corporate Communications
    • 7.1.1 Apr 07, 2025: Ono Pharmaceutical Makes Changes of Board of Directors and Corporate Officers
    • 7.1.2 Aug 23, 2024: Caris Life Sciences Announces Appointment of Dave Fredrickson to Board of Directors
  • 7.2 Financial Announcements
    • 7.2.1 May 08, 2025: Ono Pharmaceutical Reports Results for Fiscal Year Ended March 31, 2025
    • 7.2.2 Nov 08, 2024: Human Metabolome Announces Consolidated Financial Results for the First Quarter of Fiscal Year Ending June 30, 2025
    • 7.2.3 Aug 01, 2024: Astellas Pharma Announces Financial Results for Q1 FY2024
  • 7.3 Government and Public Interest
    • 7.3.1 May 08, 2025: Number of Patients Registered for Cancer Gene Panel Testing Under Health Insurance Coverage Reaches 100,000
  • 7.4 Other Significant Developments
    • 7.4.1 Feb 21, 2025: The OhmX RAMP UP Grant Awarded to 15 Laboratories to Advance Genomic Research
  • 7.5 Product News
    • 7.5.1 Nov 07, 2024: Nec and Nec Bio Publish Foundational Work on T Cell Receptor Engineering Using Proprietary Generative AI at the Society for Immunotherapy of Cancer Annual Meeting
    • 7.5.2 Nov 05, 2024: National Cancer Center, Premia, and Paradigm Launch Treatment Development Platform "LC-SCRUM-CD''
    • 7.5.3 Sep 26, 2024: Takara Bio Europe Unveils New Large-Scale NGS Profiling System and Chemistries
    • 7.5.4 Sep 24, 2024: Industry-Academia Collaboration Nationwide Cancer Genome Screening SCRUM-Japan Launches Fifth Project
    • 7.5.5 Sep 20, 2024: Approval for Manufacturing and Marketing of "Hemcyte(R)," Japan's First Gene Panel Test for Hematopoietic Tumors
    • 7.5.6 Sep 17, 2024: Liquid Biopsy Confirmed to Be Useful in Deciding on Adjuvant Therapy After Surgery for Colorectal Cancer Liver Metastases
    • 7.5.7 Sep 17, 2024: Scrum-Japan Gozila Project: Large-Scale Study of Over 4,000 Cases Confirms Extension of Survival Time Through Personalized Cancer Medicine
    • 7.5.8 Aug 01, 2024: Development of a Method to Predict Onset of Non-Alcoholic Fatty Liver Disease -Contributing to Preventive Healthcare for Lifestyle Diseases
    • 7.5.9 Jul 08, 2024: Noninvasive Urine Test for Early Detection of Cervical Cancer Virus Proteins
  • 7.6 Strategy And Business Planning
    • 7.6.1 Apr 28, 2025: PredxBio and Hamamatsu Photonics Announce Strategic Partnership to Deliver Next-Generation Spatial Biology Solutions for Cancer Research and Therapeutic Development
    • 7.6.2 Apr 15, 2025: BCAN Announces Partnerships With Ferring Pharmaceuticals and Astellas/Pfizer Alliance
    • 7.6.3 Apr 14, 2025: JelloX Biotech Establishes US Research Base
    • 7.6.4 Jul 01, 2024: NURA Health Screening Center Opens in Hanoi, Vietnam

8 Appendix

  • 8.1 Research Methodology
    • 8.1.1 Coverage
    • 8.1.2 Secondary Research
    • 8.1.3 Primary Research
    • 8.1.4 Market Modeling and Forecasting
    • 8.1.5 Company Share Analysis
    • 8.1.6 Benchmarking
  • 8.2 GlobalData Consulting
  • 8.3 Contact Us
  • 8.4 Disclaimer
Product Code: GDME25619CCDB

List of Table

List of Tables

  • Table 1: Oncology Market, Japan, Revenue ($m), USD Constant, 2018-2033
  • Table 2: ALK Tests Market, Japan, Revenue ($m), USD Constant, 2018-2033
  • Table 3: BCR-ABL Tests Market, Japan, Revenue ($m), USD Constant, 2018-2033
  • Table 4: BRAF Tests Market, Japan, Revenue ($m), USD Constant, 2018-2033
  • Table 5: BRCA Tests Market, Japan, Revenue ($m), USD Constant, 2018-2033
  • Table 6: Colorectal Cancer Screening Tests Market, Japan, Revenue ($m), USD Constant, 2018-2033
  • Table 7: EGFR Tests Market, Japan, Revenue ($m), USD Constant, 2018-2033
  • Table 8: HER2 Tests Market, Japan, Revenue ($m), USD Constant, 2018-2033
  • Table 9: KRAS Tests Market, Japan, Revenue ($m), USD Constant, 2018-2033
  • Table 10: Oncology Market, Japan, Volume (Units), 2018-2033
  • Table 11: ALK Tests Market, Japan, Volume (Units), 2018-2033
  • Table 12: BCR-ABL Tests Market, Japan, Volume (Units), 2018-2033
  • Table 13: BRAF Tests Market, Japan, Volume (Units), 2018-2033
  • Table 14: BRCA Tests Market, Japan, Volume (Units), 2018-2033
  • Table 15: Colorectal Cancer Screening Tests Market, Japan, Volume (Units), 2018-2033
  • Table 16: EGFR Tests Market, Japan, Volume (Units), 2018-2033
  • Table 17: HER2 Tests Market, Japan, Volume (Units), 2018-2033
  • Table 18: KRAS Tests Market, Japan, Volume (Units), 2018-2033
  • Table 19: Oncology Market, Japan, Average Price ($), 2018-2033
  • Table 20: Oncology Market, Japan, Company Share by Revenue ($m), 2024
  • Table 21: Oncology Market Pipeline Products
  • Table 22: Astellas Pharma Prices USD545.6 Million in Public Offering of 0.87% Series 5 Unsecured Bonds Due 2029
  • Table 23: Astellas Pharma Prices USD136.4 Million in Public Offering of 1.038% Series 6 Unsecured Bonds Due 2031
  • Table 24: The IT Lab Secures Venture Financing
  • Table 25: Total Number of Primary Research Participants, In Vitro Diagnostics Market, by Country

List of Figure

List of Figures

  • Figure 1: Oncology Market, Japan, Revenue ($m), USD Constant, 2018-2033
  • Figure 2: ALK Tests Market, Japan, Revenue ($m), USD Constant, 2018-2033
  • Figure 3: BCR-ABL Tests Market, Japan, Revenue ($m), USD Constant, 2018-2033
  • Figure 4: BRAF Tests Market, Japan, Revenue ($m), USD Constant, 2018-2033
  • Figure 5: BRCA Tests Market, Japan, Revenue ($m), USD Constant, 2018-2033
  • Figure 6: Colorectal Cancer Screening Tests Market, Japan, Revenue ($m), USD Constant, 2018-2033
  • Figure 7: EGFR Tests Market, Japan, Revenue ($m), USD Constant, 2018-2033
  • Figure 8: HER2 Tests Market, Japan, Revenue ($m), USD Constant, 2018-2033
  • Figure 9: KRAS Tests Market, Japan, Revenue ($m), USD Constant, 2018-2033
  • Figure 10: Oncology Market, Japan, Volume (Units), 2018-2033
  • Figure 11: ALK Tests Market, Japan, Volume (Units), 2018-2033
  • Figure 12: BCR-ABL Tests Market, Japan, Volume (Units), 2018-2033
  • Figure 13: BRAF Tests Market, Japan, Volume (Units), 2018-2033
  • Figure 14: BRCA Tests Market, Japan, Volume (Units), 2018-2033
  • Figure 15: Colorectal Cancer Screening Tests Market, Japan, Volume (Units), 2018-2033
  • Figure 16: EGFR Tests Market, Japan, Volume (Units), 2018-2033
  • Figure 17: HER2 Tests Market, Japan, Volume (Units), 2018-2033
  • Figure 18: KRAS Tests Market, Japan, Volume (Units), 2018-2033
  • Figure 19: Oncology Market, Japan, Company Share (%), 2024
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!